No retraction, correction or concern found when last checked on Oct 29, 2026.

Escape from neutralizing antibodies by SARS-CoV-2 spike protein variants

Yiska Weisblum, Fabian Schmidt, Fengwen Zhang and 21 more

eLife · 2020 · CC BY

doi:10.1101/2020.07.21.214759

Abstract

Neutralizing antibodies elicited by prior infection or vaccination are likely to be key for future protection of individuals and populations against SARS-CoV-2. Moreover, passively administered antibodies are among the most promising therapeutic and prophylactic anti-SARS-CoV-2 agents. However, the degree to which SARS-CoV-2 will adapt to evade neutralizing antibodies is unclear. Using a recombinant chimeric VSV/SARS-CoV-2 reporter virus, we show that functional SARS-CoV-2 S protein variants with mutations in the receptor-binding domain (RBD) and N-terminal domain that confer resistance to monoclonal antibodies or convalescent plasma can be readily selected. Notably, SARS-CoV-2 S variants that resist commonly elicited neutralizing antibodies are now present at low frequencies in circulating SARS-CoV-2 populations. Finally, the emergence of antibody-resistant SARS-CoV-2 variants that might limit the therapeutic usefulness of monoclonal antibodies can be mitigated by the use of antibody combinations that target distinct neutralizing epitopes.

References 58

1.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
2.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
3.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
4.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
5.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
6.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
7.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
8.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
9.
Data, disease and diplomacy: GISAID's innovative contribution to global health · 2017
No notice
10.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
11.
Combination of quadruplex qPCR and next-generation sequencing for qualitative and quantitative analysis of the HIV-1 latent reservoir · 2019
No notice
12.
Structural basis for the recognition of SARS-CoV-2 by full-length human ACE2 · 2020
No notice
13.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
14.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
15.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
16.
The dynamics of humoral immune responses following SARS-CoV-2 infection and the potential for reinfection · 2020
No notice
17.
Human monoclonal antibodies block the binding of SARS-CoV-2 spike protein to angiotensin converting enzyme 2 receptor · 2020
No notice
18.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
19.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
20.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
21.
A noncompeting pair of human neutralizing antibodies block COVID-19 virus binding to its receptor ACE2 · 2020
No notice
22.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
23.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
24.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
25.
Studies in humanized mice and convalescent humans yield a SARS-CoV-2 antibody cocktail · 2020
No notice
26.
Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability · 2020
No notice
27.
Antibody cocktail to SARS-CoV-2 spike protein prevents rapid mutational escape seen with individual antibodies · 2020
No notice
28.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
29.
Broad neutralization of SARS-related viruses by human monoclonal antibodies · 2020
No notice
30.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
31.
Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model · 2020
No notice
32.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
33.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
34.
A neutralizing human antibody binds to the N-terminal domain of the Spike protein of SARS-CoV-2 · 2020
No notice
35.
Structures of Human Antibodies Bound to SARS-CoV-2 Spike Reveal Common Epitopes and Recurrent Features of Antibodies · 2020
No notice
36.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
37.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
38.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
39.
Structural basis of a shared antibody response to SARS-CoV-2 · 2020
No notice
40.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library

All 58 references

Cited by papers we hold 53

Fitness effects of mutations to SARS-CoV-2 proteins · 2023
No notice
Convergent Evolution in SARS-CoV-2 Spike Creates a Variant Soup from Which New COVID-19 Waves Emerge · 2023
No notice
Targeted escape of SARS-CoV-2 in vitro from monoclonal antibody S309, the precursor of sotrovimab · 2022
Not checked
How to Deal With Vaccine Breakthrough Infection With SARS-CoV-2 Variants · 2022
Not checked
Tracking cryptic SARS-CoV-2 lineages detected in NYC wastewater · 2022
Corrected
Structural and functional characterizations of infectivity and immune evasion of SARS-CoV-2 Omicron · 2022
Corrected
SARS-CoV-2 variants of concern surveillance including Omicron using RT-PCR–based genotyping offers comparable performance to whole genome sequencing · 2022
Not checked
Emergence of a novel SARS-CoV-2 Pango lineage B.1.1.526 in West Bengal, India · 2022
Not checked
Mutations and Evolution of the SARS-CoV-2 Spike Protein · 2022
Corrected
Analysis of 6.4 million SARS-CoV-2 genomes identifies mutations associated with fitness · 2022
No notice
SARS-CoV-2-Specific Immune Response and the Pathogenesis of COVID-19 · 2022
No notice
A Detailed Overview of Immune Escape, Antibody Escape, Partial Vaccine Escape of SARS-CoV-2 and Their Emerging Variants With Escape Mutations · 2022
No notice
SARS-CoV-2 Omicron is an immune escape variant with an altered cell entry pathway · 2022
Corrected
Vaccine-induced systemic and mucosal T cell immunity to SARS-CoV-2 viral variants · 2022
No notice
SARS-CoV-2 Variants, Vaccines, and Host Immunity · 2022
No notice
The SARS-CoV-2 mutations versus vaccine effectiveness: New opportunities to new challenges · 2022
No notice
Genomic Evidence of SARS-CoV-2 Reinfection Involving E484K Spike Mutation, Brazil · 2021
No notice
Evidence for increased breakthrough rates of SARS-CoV-2 variants of concern in BNT162b2-mRNA-vaccinated individuals · 2021
No notice
Meta-Analysis and Structural Dynamics of the Emergence of Genetic Variants of SARS-CoV-2 · 2021
Not checked
Mutation Rates, Mutation Frequencies, and Proofreading-Repair Activities in RNA Virus Genetics · 2021
No notice

and 33 more

Reads

Read by people on this page

None yet.

Checked or read by AI through naulon

None yet.

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.

Are you an author?

Is this your paper?

Claim it to add your note and be paid when agents cite it. Free.